US Hereditary Angioedema Therapeutics Market

ID: MRFR/HC/15214-HCR
100 Pages
Nidhi Mandole
Last Updated: April 06, 2026
US Hereditary Angioedema Therapeutics Market Research Report: Size, Share, Trend Analysis By Types (Type I, Type II), By Drug Class (C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Others), By Treatment (Prophylaxis - Long-term Prophylaxis, Short-term Prophylaxis, On-demand), By Route of Administration (Intravenous, Subcutaneous, Oral) and By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) - Growth Outlook & Industry Forecast 2025 To 2035
US Hereditary Angioedema Therapeutics Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)4.1%
2024 Market Size$ 1,761.4 Million
2025 Market Size$ 1,833.62 Million
2035 Market Size$ 2,739.7 Million
Key Players
Takeda Pharmaceutical Company Limited
CSL Behring
Shire
Pharming Group N.V.
BioCryst Pharmaceuticals
Inc.
Trends
  • Emergence of Targeted Therapies
  • Increased Patient Awareness and Education
  • Regulatory and Reimbursement Developments
Opportunities
  • Advancements in Biotechnology
  • Enhanced Regulatory Frameworks
  • Increased Focus on Personalized Medicine
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Food, Beverages & Nutrition, BY Type (USD Million)
      1. 4.1.1 Type I
      2. 4.1.2 Type II
    2. 4.2 Food, Beverages & Nutrition, BY Drug Class (USD Million)
      1. 4.2.1 C1 Esterase Inhibitor
      2. 4.2.2 Selective Bradykinin B2 Receptor Antagonist
      3. 4.2.3 Kallikrein Inhibitor
      4. 4.2.4 Others
    3. 4.3 Food, Beverages & Nutrition, BY Treatment (USD Million)
      1. 4.3.1 Prophylaxis
      2. 4.3.2 On-demand
    4. 4.4 Food, Beverages & Nutrition, BY Route of Administration (USD Million)
      1. 4.4.1 Intravenous
      2. 4.4.2 Subcutaneous
      3. 4.4.3 Oral
    5. 4.5 Food, Beverages & Nutrition, BY Distribution Channel (USD Million)
      1. 4.5.1 Hospital Pharmacy
      2. 4.5.2 Retail Pharmacy
      3. 4.5.3 Online Pharmacy
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Food, Beverages & Nutrition
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Food, Beverages & Nutrition
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Takeda Pharmaceutical Company Limited (JP)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 CSL Behring (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Shire (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Pharming Group N.V. (NL)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 BioCryst Pharmaceuticals, Inc. (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Sobi (SE)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Ferring Pharmaceuticals (CH)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Grifols S.A. (ES)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY TYPE
    3. 6.3 US MARKET ANALYSIS BY DRUG CLASS
    4. 6.4 US MARKET ANALYSIS BY TREATMENT
    5. 6.5 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    6. 6.6 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    7. 6.7 KEY BUYING CRITERIA OF FOOD, BEVERAGES & NUTRITION
    8. 6.8 RESEARCH PROCESS OF MRFR
    9. 6.9 DRO ANALYSIS OF FOOD, BEVERAGES & NUTRITION
    10. 6.10 DRIVERS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
    11. 6.11 RESTRAINTS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
    12. 6.12 SUPPLY / VALUE CHAIN: FOOD, BEVERAGES & NUTRITION
    13. 6.13 FOOD, BEVERAGES & NUTRITION, BY TYPE, 2024 (% SHARE)
    14. 6.14 FOOD, BEVERAGES & NUTRITION, BY TYPE, 2024 TO 2035 (USD Million)
    15. 6.15 FOOD, BEVERAGES & NUTRITION, BY DRUG CLASS, 2024 (% SHARE)
    16. 6.16 FOOD, BEVERAGES & NUTRITION, BY DRUG CLASS, 2024 TO 2035 (USD Million)
    17. 6.17 FOOD, BEVERAGES & NUTRITION, BY TREATMENT, 2024 (% SHARE)
    18. 6.18 FOOD, BEVERAGES & NUTRITION, BY TREATMENT, 2024 TO 2035 (USD Million)
    19. 6.19 FOOD, BEVERAGES & NUTRITION, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
    20. 6.20 FOOD, BEVERAGES & NUTRITION, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
    21. 6.21 FOOD, BEVERAGES & NUTRITION, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
    22. 6.22 FOOD, BEVERAGES & NUTRITION, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
    23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.2.2 BY DRUG CLASS, 2025-2035 (USD Million)
      3. 7.2.3 BY TREATMENT, 2025-2035 (USD Million)
      4. 7.2.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
      5. 7.2.5 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US Hereditary Angioedema Therapeutics Market Segmentation

US Hereditary Angioedema Therapeutics Market By Type (USD Million, 2025-2035)

  • Type I
  • Type II

US Hereditary Angioedema Therapeutics Market By Drug Class (USD Million, 2025-2035)

  • C1 Esterase Inhibitor
  • Selective Bradykinin B2 Receptor Antagonist
  • Kallikrein Inhibitor
  • Others

US Hereditary Angioedema Therapeutics Market By Treatment (USD Million, 2025-2035)

  • Prophylaxis
  • On-demand

US Hereditary Angioedema Therapeutics Market By Route of Administration (USD Million, 2025-2035)

  • Intravenous
  • Subcutaneous
  • Oral

US Hereditary Angioedema Therapeutics Market By Distribution Channel (USD Million, 2025-2035)

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.